Bu-Fei Yi-Shen Granules Reduce Acute Exacerbations in Patients with GOLD 3–4 COPD: A Randomized Controlled Trial

References

• Kendrick PJ, Paulson KR, Gupta V, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Resp Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China pulmonary health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
   PubMed Web of Science ®Google Scholar
• Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Resp Med. 2018;6(6):421–430. doi:10.1016/S2213-2600(18)30103-6
   PubMed Web of Science ®Google Scholar
• Yin P, Wu J, Wang L, et al. The burden of COPD in China and Its provinces: findings from the global burden of disease study 2019. Front Public Health. 2022;10:859499. doi:10.3389/fpubh.2022.859499
   PubMedGoogle Scholar
• Flattet Y, Garin N, Serratrice J, Perrier A, Stirnemann J, Carballo S. Determining prognosis in acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:467–475. doi:10.2147/COPD.S122382
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.847
   PubMed Web of Science ®Google Scholar
• Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626. doi:10.1016/S2213-2600(17)30207-2
   PubMed Web of Science ®Google Scholar
• Horita N, Miyazawa N, Morita S, et al. Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease. Respir Res. 2014;15(1):37. doi:10.1186/1465-9921-15-37
   PubMedGoogle Scholar
• van den Berge M, De Backer J, Van Holsbeke C, et al. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids. Respir Res. 2021;22(1):191. doi:10.1186/s12931-021-01772-2
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Triple inhaler versus dual bronchodilator therapy in COPD: real-world effectiveness on mortality. J Chron Obstruct Pulmon Dis. 2022;19(1):1–9. doi:10.1080/15412555.2021.1977789
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Single-inhaler triple versus dual bronchodilator therapy in COPD: real-world comparative effectiveness and safety. Int J Chron Obstruct Pulmon Dis. 2022;17:1975–1986. doi:10.2147/COPD.S378486
   PubMed Web of Science ®Google Scholar
• Jian-Sheng L. Positive deficiency and accumulated damage is the core TCM pathogenesis of chronic obstructive pulmonary disease. Chin J Traditional Chin Med. 2011;26(08):710–713.
   Google Scholar
• Li JS, Li SY, Xie Y, et al. The effective evaluation on symptoms and quality of life of chronic obstructive pulmonary disease patients treated by comprehensive therapy based on traditional Chinese medicine patterns. Complement Ther Med. 2013;21(6):595–602. doi:10.1016/j.ctim.2013.09.006
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2019. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed October 18, 2023.
   Google Scholar
• Expert Group on the Diagnosis and Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Chinese expert consensus on the diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (2017 update). Int J Resp. 2017;37(14):1041–1057.
   Google Scholar
• Li JS. Diagnostic criteria for traditional Chinese medicine syndromes of chronic obstructive pulmonary disease (2011 Edition). J Traditional Chin Med. 2012;53(2):177–178.
   Google Scholar
• Huang J, Bian Y, Zhao Y, Jin Z, Liu L, Li G. The impact of depression and anxiety on chronic obstructive pulmonary disease acute exacerbations: a prospective cohort study. J Affect Disord. 2021;281:147–152. doi:10.1016/j.jad.2020.12.030
   PubMed Web of Science ®Google Scholar
• Montserrat-Capdevila J, Godoy P, Marsal JR, Barbé F, Galván L. Risk factors for exacerbation in chronic obstructive pulmonary disease: a prospective study. Int J Tuberc Lung Dis. 2016;20(3):389–395. doi:10.5588/ijtld.15.0441
   PubMed Web of Science ®Google Scholar
• Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J. 2016;47(1):113–121. doi:10.1183/13993003.01391-2014
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.040527
   PubMed Web of Science ®Google Scholar
• Casanova C, Marin JM, Martinez-Gonzalez C, et al. Differential effect of modified Medical Research Council dyspnea, COPD assessment test, and clinical COPD questionnaire for symptoms evaluation within the new GOLD staging and mortality in COPD. Chest. 2015;148(1):159–168. doi:10.1378/chest.14-2449
   PubMed Web of Science ®Google Scholar
• Sundh J, Ekström M. Persistent disabling breathlessness in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:2805–2812. doi:10.2147/COPD.S119992
   PubMed Web of Science ®Google Scholar
• Lee SD, Huang MS, Kang J, et al. The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patients. Resp Med. 2014;108(4):600–608. doi:10.1016/j.rmed.2013.12.014
   PubMed Web of Science ®Google Scholar
• Hopkinson NS, Tennant RC, Dayer MJ, et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respir Res. 2007;8(1):25. doi:10.1186/1465-9921-8-25
   PubMedGoogle Scholar
• Yu XQ, Wang MH, Li JS, et al. Effect of comprehensive therapy based on Chinese medicine patterns on self-efficacy and effectiveness satisfaction in chronic obstructive pulmonary disease patients. Chin J Integr Med. 2019;25(10):736–742. doi:10.1007/s11655-017-2417-9
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-8
   PubMed Web of Science ®Google Scholar
• Muro S, Sugiura H, Darken P, Dorinsky P. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts. Respir Res. 2021;22(1):187. doi:10.1186/s12931-021-01773-1
   PubMed Web of Science ®Google Scholar
• Zeng Y, Li Y, Wei H, et al. The effects and safety of Chinese oral herbal paste on stable chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. J Evid Based Complementary Altern Med. 2020;2020:5867086.
   Google Scholar
• Sun Y, Chen X, Zhang L, et al. Efficiency and safety of baofei granules in chronic obstructive pulmonary disease (lung and spleen qi deficiency syndrome): a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial. Drug Des Devel Ther. 2022;16:4251–4267. doi:10.2147/DDDT.S382285
   PubMed Web of Science ®Google Scholar
• Mao Y, Hu G, Meng Q, et al. Efficacy of Shenling Baizhu San on stable chronic obstructive pulmonary disease patients: a systematic review and meta-analysis. J Ethnopharmacol. 2021;272:113927. doi:10.1016/j.jep.2021.113927
   PubMed Web of Science ®Google Scholar
• Li SY, Li JS, Wang MH, et al. Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study. BMC Complement Altern Med. 2012;12:197. doi:10.1186/1472-6882-12-197
   PubMed Web of Science ®Google Scholar
• Haifeng W, Jiansheng L, Suyun L, et al. Effect of sequential treatment with syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and “AECOPD Risk-Window”: study protocol for a randomized placebo-controlled trial. Trials. 2012;13(1):40. doi:10.1186/1745-6215-13-40
   PubMedGoogle Scholar